Targeting the Warburg effect in hematological malignancies: From PET to therapy

Current Opinion in Oncology

Volumn 21, Issue 6, 2009, Pages 531-536

  Shanmugam, Mala ^a   McBrayer, Samuel K ^a   Rosen, Steven T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Glucose; Glycolysis; Hematologic malignancies

Indexed keywords

BCR ABL PROTEIN; CISPLATIN; DIAZEPAM; DICHLOROACETIC ACID; DOCETAXEL; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUTAMINE; LONIDAMINE; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BIOENERGY; BREAST CANCER; CANCER CELL CULTURE; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; GLIOBLASTOMA; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCOLYSIS; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; MITOCHONDRION; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SOLID TUMOR; TUMOR CELL; WALKER WARBURG SYNDROME; BIOLOGICAL MODEL; BLOOD DISEASE; DRUG EFFECT; METABOLISM; METHODOLOGY; OXYGEN CONSUMPTION;

ANTINEOPLASTIC AGENTS; GLUCOSE; GLYCOLYSIS; HEMATOLOGIC NEOPLASMS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; OXYGEN CONSUMPTION; POSITRON-EMISSION TOMOGRAPHY;

EID: 74049160403     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32832f57ec     Document Type: Review

References (49)

1. Degos L, Linch DC, Lowenberg B, editors. Textbook of malignant hematology. 2nd ed. Taylor and Francis; 2005.
2. Warburg O. On the origin of cancer cells. Science 1956; 123:309-314.
3. Stryer L. Biochemistry. 3rd ed. New York: W.H. Freeman Company; 1988.
4. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006; 9:425-434. (Pubitemid 43832190)
5. Schulz TJ, Thlerbach R, Voigt A, et al. Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited. J Biol Chem 2006;281:977-981.
6. Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007; 11:37-51.
7. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452:230-233.
8. Pecqueur C, Bui T, Gelly C, et al. Uncoupling protein-2 controls proliferation by promoting fatty acid oxidation and limiting glycolysls-derived pyruvate utilization. FASEB J 2008; 22:9-18.
9. Derdak Z, Mark NM, Beldi G, et al. The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. Cancer Res 2008; 68:2813-2819. (Pubitemid 351556280)
10. Ramanathan A, Wang C, Schreiber SL Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci U S A 2005; 102:5992-5997. (Pubitemid 40594243)
11. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25:4633-4646.
12. Osthus RC, Shim H, Kim S, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000; 275:21797-21800. (Pubitemid 30621745)
13. Guppy M, Greiner E, Brand K. The role of the Crabtree effect and an endogenous fuel in the energy metabolism of resting and proliferating thymocytes. Eur J Biochem 1993; 212:95-99. (Pubitemid 23064604)
14. Bui T, Thompson CB. Cancer's sweet tooth. Cancer Cell 2006; 9:419-420.
15. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 2007; 104:19345-19350.
16. Mathupala SP, Ko YH, Pedersen PL. Hexokliase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006; 25:4777-4786.
17. Gottlob K, Majewski N, Kennedy S, et al. Inhibition of early apoptotic events by Akt/PKB Is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 2001; 15:1406-1418. (Pubitemid 32524647)
18. Zhao Y, Altman BJ, Coloff JL, et al. Glycogen synthase kinase 3alpha and 3beta mediate a glucose-sensitive antiapoptotlc signaling pathway to stabilize Mcl-1. Mol Cell Biol 2007; 27:4328-4339. (Pubitemid 46906557)
19. Danial NN, Gramm CF, Scorrano L, et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 2003; 424:952-956. (Pubitemid 37051687)
20. Rathmell JC, Fox CJ, Plas DR, et al. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 2003; 23:7315-7328.
21. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4:891-899.
22. Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously overex-pressed in 24 cancer classes. Genomics 2004; 84:1014-1020. (Pubitemid 39469126)
23. Boag JM, Beesley AH, Firth MJ, et al. Altered glucose metabolism in childhood pre-B acute lymphoblastic leukaemia. Leukemia 2006; 20:1731-1737. (Pubitemid 44574984)
24. Kim JH, Chu SC, Gramlich JL, et al. Activation of the Pl3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 2005; 105:1717-1723. (Pubitemid 40223695)
25. Samudlo I, Fieg M, McQueen T, et al. The Warburg effect in leukemla-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer Res 2008; 68:5198-5205.
26. Durie BG, Waxman AD, D'Agnolo A, Williams CM. Whole-body (18)F-FDG PET Identifies high-risk myeloma. J Nucl Med 2002; 43:1457-1463.
27. Bredella MA, Steinbach L, Caputo G, et al. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol 2005; 184:1199-1204. (Pubitemid 43821897)
28. Hedeskov CJ. Early effects of phytohaemagglutinin on glucose metabolism of normal human lymphocytes. Biochem J 1968; 110:373-380.
29. Roos D, Loos JA. Changes in the carbohydrate metabolism of mitogenlcally stimulated human peripheral lymphocytes. II: Relative importance of glycolysis and oxidative phosphorylation on phytohaemagglutlnln stimulation. Exp Cell Res 1973; 77:127-135.
30. Hutchings M, Specht L PET/CT in the management of haematological malignancies. Eur J Haematol 2008; 80:369-380.
31. Raffaghello L, Lee C, Safdle FM, et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A 2008; 105:8215-8220. (Pubitemid 351904737)
32. Scatena R, Bottoni P, Pontoglio A, et al. Glycolytic enzyme inhibitors in cancer treatment. Expert Opin Investlg Drugs 2008; 17:1533-1545.
33. Nista A, De Martino C, Malorni W, et al. Effect of lonidamine on the aerobic glycolysis of normal and phytohemagglutlnln-stimulated human peripheral blood lymphocytes. Exp Mol Pathol 1985; 42:194-205. (Pubitemid 15096807)
34. Floridi A, Paggi MG, D'Atri S, et al. Effect of lonldamlne on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res 1981; 41 (11 Pt 1): 4661-4666. (Pubitemid 12201388)
35. Bustamante E, Pedersen PL. Mitochondrial hexokinase of rat hepatoma cells in culture: solubilization and kinetic properties. Biochemistry 1980; 19: 4972-4977. (Pubitemid 11205877)
36. Oudard S, Carpentier A, Banu E, et al. Phase II study of lonldamine and diazepam in the treatment of recurrent glioblastoma multiforme. J Neurooncol 2003; 63:81-86. (Pubitemid 36681647)
37. De Lena M, Lorusso V, Latorre A, et al. Paclitaxel, cisplatin and lonldamine in advanced ovarian cancer. A phase II study. Eur J Cancer 2001 ; 37:364-368. (Pubitemid 32182325)
38. Berruti A, Bitossi R, Gorzegno G, et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. J Clin Oncol 2002; 20:4150-4159.
39. Hulleman E, Kazemler KM, Holleman A, et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 2009; 113:2014-2021.
40. Raez LE, Langmuir VK, Papadopoulus K, et al. Phase I trial of glycolitic inhibition with 2-deoxyglucose and docetaxel for patients with solid tumors. AACR Meet Abstr 2006; 2006:121-d-2.
41. Maschek G, Savaraj N, Priebe W, et al. 2-Deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and nonsmall cell lung cancers in vivo. Cancer Res 2004; 64:31-34. (Pubitemid 38114078)
42. Zhong D, Liu X, Schafer-Hales K, et al. 2-Deoxyglucose induces Akt phosphorylation via a mechanism Independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. Mol Cancer Ther 2008; 7:809-817. (Pubitemid 351551034)
43. Dearling JL, Qureshi U, Begent RH, Pedley RB. Combining radioimmunotherapy with antihypoxia therapy 2-deoxy-D-glucose results in reduction of therapeutic efficacy. Clin Cancer Res 2007; 13:1903-1910. (Pubitemid 46952961)
44. Kim JW, Gao P, Liu YC, et al. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexoklnase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 2007; 27:7381-7393. (Pubitemid 350033646)
45. Stacpoole PW, Kerr DS, Barnes C, et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 2006; 117:1519-1531.
46. Pouyssegur J, Chiche J, Ilc K, et al. Tumor cell resistance to hypoxic and acidic stresses. Key roles of HIF-induced BNIPs, carbonic anhydrases and MCTs [abstract]. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr SY33-3.
47. Sonveaux P, Vegran F, Schroeder T, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008; 118:3930-3942.
48. Degenhardt K, Mathew R, Beaudoin B, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006; 10:51-64.
49. Lum JJ, Bauer DE, Kong M, et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005; 120:237-248. (Pubitemid 40174766)